CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis Lifestyle Modifications for Preventing and Treating Heart Failure INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)

Original ResearchVolume 3, Issue 5, October 2018

JOURNAL:JACC: Basic to Translational Science Article Link

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors

S Verma, S Rawat, KL Ho et al. Keywords: cardiac efficiency; db/db; glucose oxidation; ketone oxidation; sodium-glucose co-transporter-2 inhibitors

FULL TEXT PDF